Name

MBX Biosciences

Legal name

MBX Biosciences, Inc.

Website

https://mbxbio.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Endocrine and Metabolic Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industries

Mental Health Parity (MHPAEA) Compliance & Reporting (HLAEAHAG), Rare Endocrine & Growth Disorder Therapies (HLAIAIAJ), Companion Diagnostics (CDx) & Precision Medicine IVD (HLAHAAAJ), Pharmacogenomics (PGx) Decision Support (HLAAANAB)

Keywords

• Precision peptide therapeutics
• Endocrine disorder treatments
• Metabolic disease therapies
• Peptide hormone engineering
• Clinical-stage biopharmaceutical

Headquarters

HQ city

Carmel

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pre-revenue / No product revenue: MBX Biosciences is a clinical-stage biopharmaceutical company with no approved products and no current product revenue. Operations are funded through equity financing (Series B $115M, Series C $63.5M, ATM offering ~$87.1M) with cumulative funding of over $213 million as of August 2024.
2. Future potential product sales (post-approval): Future revenue from canvuparatide (MBX 2109) for hypoparathyroidism, with analysts modeling peak worldwide sales exceeding $3 billion (Citizens Financial Group). Future product revenue expected from MBX 4291 and MBX 5765 obesity candidates and other pipeline assets once approved.

Pricing tiers

Go-to-market motion3 records

Distribution channels1 record

Marketing channels8 records

Core offering

MBX Biosciences is a clinical-stage biopharmaceutical company developing a portfolio of investigational precision endocrine peptide (PEP) therapeutics for endocrine and metabolic disorders. Its lead clinical asset is canvuparatide (MBX 2109), a once-weekly subcutaneous parathyroid hormone (PTH) replacement therapy for chronic hypoparathyroidism that has completed a Phase 2 Avail trial and is advancing into a Phase 3 trial planned for Q3 2026. The pipeline also includes MBX 4291 (GLP-1/GIP co-agonist prodrug for obesity with once-monthly dosing target), MBX 5765 (amycretin prodrug combining GLP-1, GIP, glucagon, and amylin/calcitonin activity), MBX 6XXX (GLP-1/GIP/GCGR triple-agonist prodrug), and imapextide (MBX 1416), a long-acting GLP-1 receptor antagonist that reported proof of concept in post-bariatric hypoglycemia.

Product overview

MBX Biosciences is a clinical-stage biopharmaceutical company built around a single unified proprietary discovery and engineering platform — the Precision Endocrine Peptide (PEP™) platform — from which a portfolio of named product candidates is being advanced. The lead clinical asset, Canvuparatide (MBX 2109), is a once-weekly PTH replacement therapy for chronic hypoparathyroidism advancing into Phase 3. The obesity portfolio is a modular set of differentiated candidates generated by the same platform: MBX 4291, a long-acting GLP-1/GIP co-agonist prodrug in Phase 1 with a once-monthly dosing target; MBX 5765, a recently nominated amycretin prodrug entering IND-enabling studies; and MBX 6XXX, a GLP-1/GIP/GCGR triple-agonist prodrug in discovery. The portfolio also includes Imapextide (MBX 1416), a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia that reported proof of concept. Together, the PEP platform and its product candidates (Canvuparatide, MBX 4291, MBX 5765, MBX 6XXX, Imapextide) form a coordinated platform-plus-candidates architecture aimed at endocrine and metabolic disorders.

Differentiator

Problem solved

Functional benefit

Products and services

• Canvuparatide (MBX 2109) Investigational once-weekly subcutaneous parathyroid hormone (PTH) replacement therapy designed to provide continuous, infusion-like PTH exposure for the treatment of chronic hypoparathyroidism in adults. Phase 2 Avail trial showed 63% responder rate at 12 weeks vs. 31% placebo, with one-year open-label extension data demonstrating 57% responder rate and 90% patient retention and sustained calcium normalization plus improved kidney function. Has received FDA and EMA orphan drug designation.
• MBX 4291 Long-acting Precision Endocrine Peptide (PEP) GLP-1/GIP co-agonist prodrug designed for potential once-monthly subcutaneous dosing in adult obesity. Preliminary Phase 1 MAD data demonstrated 7% mean weight loss at 8 weeks (range 0–16%) with a half-life of approximately 26 days supporting once-monthly dosing; full 12-week MAD Part C data expected Q4 2026.
• MBX 5765 Lead amycretin prodrug development candidate on the PEP platform. A single peptide construct combining GLP-1, GIP, glucagon, and dual amylin and calcitonin receptor agonist (DACRA) activity, designed for once-monthly subcutaneous dosing, superior efficacy, and improved tolerability in obesity. IND-enabling studies planned to begin in Q2 2026.
• MBX 6XXX GLP-1/GIP/GCGR (glucagon receptor) triple-agonist prodrug being developed on the PEP platform as a potential treatment for obesity. Triple G prodrug candidate nomination is expected in Q3 2026.
• Imapextide (MBX 1416) Long-acting GLP-1 receptor antagonist (PEP) evaluated in a Phase 1 trial for post-bariatric hypoglycemia, a complication of bariatric surgery characterized by dangerously low blood sugar. The Phase 1 trial completed the final subject's last visit in November 2024; the company reported imapextide achieved proof of concept in this indication in May 2026.

Quantifiable outcome

• 63% responder rate at 12 weeks (vs. 31% placebo) in Phase 2 Avail trial of canvuparatide
• +4 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Ascendis Pharma: Clinical and early-commercial stage biotech developing TransCon PTH (palopegteriparatide) for chronic hypoparathyroidism — the most direct competitor to canvuparatide in the same indication with similar PTH replacement mechanism.
• Crinetics Pharmaceuticals: Clinical-stage rare endocrine disease biotech (paltusotine for acromegaly) with comparable size, stage, and orphan-disease strategy focused on peptide therapeutics for endocrine disorders.
• Structure Therapeutics: Clinical-stage biotech developing oral and non-injectable peptide candidates for endocrine and metabolic diseases including obesity (GSBR-1290), closely comparable in therapeutic focus and modality to MBX's PEP-derived candidates.
• Viking Therapeutics: Clinical-stage biotech developing peptide-based therapies for metabolic diseases including VK2735 (GLP-1/GIP dual agonist) for obesity — directly comparable to MBX 4291 in mechanism and indication.
• Rhythm Pharmaceuticals: Commercial-stage rare endocrine disease biotech (IMCIVREE / setmelanotide for MC4R pathway obesities) with overlapping rare-endocrine specialty physician call point and orphan-drug commercial model.
• Soleno Therapeutics: Clinical and early-commercial rare disease biotech (diazoxide choline extended-release for Prader-Willi syndrome hyperphagia) — comparable size, stage, and rare-endocrine metabolic focus.

Broad incumbents

• Zealand Pharma: Established peptide therapeutics company with a broader pipeline across metabolic disease (dasiglucagon for hypoglycemia) — comparable in peptide-platform focus but more mature with multiple clinical/commercial programs.
• Ultragenyx Pharmaceutical: Commercial rare disease biotech with multiple approved biologics and peptide therapeutics — relevant comparable for rare-disease commercial launch infrastructure and orphan drug strategy.
• Eli Lilly: Incumbent leader in obesity with Mounjaro/Zepbound (tirzepatide) and next-generation GLP-1 candidates — sets the competitive benchmark MBX 4291 and MBX 5765 must overcome in obesity.
• Novo Nordisk: Incumbent leader in diabetes and obesity (Ozempic/Wegovy) with established global commercial footprint — sets the competitive benchmark and scale of resources any new obesity entrant must match.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/mbxbio
• Facebookfacebook.com/profile.php?id=61572572198731&mibextid=wwXIfr
• LinkedInlinkedin.com/company/mbx-biosciences-inc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds4 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MBX Biosciences